GE HealthCare Announces Strategic Leadership and Segment Restructuring to Enhance Patient and Customer Focus

GE Healthcare announced on June 10 the appointment of Roland Rott as President and CEO of Imaging, and Phil Rackliffe as President and CEO of Ultrasound and IGT. Both leaders bring decades of extensive experience in healthcare innovation and have led global teams in scaled businesses.

This also highlights the depth of internal talent that GE HealthCare is cultivating to strengthen its focus on serving patients and customers. These changes will take effect on July 1, 2024.

IGT is a $1.6 billion imaging segment market that will merge with the ultrasound segment in the third quarter of 2024 to form a global business with annual revenues exceeding $5 billion. GE HealthCare is combining IGT with ultrasound to better align with its clinical applications and achieve greater business and customer impact by providing the right image guidance in the appropriate care setting.

Adjust IGT and ultrasound to make GE HealthCare more flexible, and use these real-time modalities to address future imaging needs in both inpatient and outpatient settings.

Without IGT, imaging would remain GE HealthCare's largest segment, with annual revenues exceeding $8.9 billion. This segment will focus on solutions centered around surgical and interventional procedures, particularly in interventional cardiology and structural heart, while maintaining a leading position in diagnostic ultrasound.

GE Healthcare CEO Peter Arduini said, "Roland and Phil will bring a fresh perspective, a global viewpoint, and deep industry expertise to our Imaging division as well as our new Ultrasound and IGT divisions. Elevating leaders with a strong understanding of customer needs, market trends, and strategic priorities will help us accelerate innovation and growth. Roland and Phil are recognized leaders who are well-positioned to seize these new opportunities, drive our Precision Care strategy, and serve patients and customers."

Roland joined GE Healthcare in 2011, holding various leadership roles within the ultrasound division before becoming President and CEO in 2021. He has an excellent track record in growing healthcare businesses and driving product innovation through digital and artificial intelligence (AI). He has played a key role in leading mergers and acquisitions, including the acquisitions of BK Medical and Caption Health, and established strategic alliances with new partners such as the Bill & Melinda Gates Foundation, BARDA, and Novo Nordisk.

He has achieved significant platform-based results in the ultrasound field, including the recently launched LOGIQ E10 series as well as the LOGIQ Fortis and Voluson Signature ultrasound systems, and will drive similar imaging platform initiatives. Before joining GE HealthCare, Roland served as a member of the executive committee at a publicly traded company and founded two software companies that were acquired by strategic investors.

Phil joined GE HealthCare in 2022, leading IGT and driving significant revenue growth for the business during his tenure. Since joining GE HealthCare, Phil has overseen R&D expansion related to new product launches, including Allia Pulse, 3DStent, EmboAssist AI, and OmnifyXR. He has also spearheaded strategic equity investments, focusing on improving visualization and surgical navigation technologies through the use of augmented reality in minimally invasive surgeries.

He has over 20 years of global experience in medical technology, medical devices, and pharmaceuticals, working with publicly traded companies including Baxter Healthcare, Boston Scientific, Pfizer, as well as Ernst & Young. Phil's last position before joining GE Healthcare was CEO of Centraline Biomedical, a spin-off from Cleveland Clinic.

GE HealthCare is expected to provide recast financial results in filings with the U.S. Securities and Exchange Commission in the third quarter of 2024 to reflect the change of IGT from Imaging to the new Ultrasound and IGT segment.